ArticleScientific reports2026
TRIM29 suppresses malignant progression in lung squamous cell carcinoma by shaping an immunosuppressive tumor microenvironment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Negative regulators antagonizing antitumor innate immune pathways in lung cancer immune evasion.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
TRIM29 (tripartite motif containing 29) is a multifunctional protein with context-dependent roles in cancer, acting as either an oncogene or a tumor suppressor. In this study, we investigated the role of TRIM29 in lung squamous cell carcinoma (LUSC) and its impact on the tumor microenvironment. We found that TRIM29 is highly expressed in early-stage LUSC, primarily due to promoter hypomethylation and copy number amplification. High TRIM29 expression was significantly associated with improved overall survival, disease-specific survival, and progression-free survival in LUSC patients. However, TRIM29 did not remain an independent prognostic factor after adjusting for clinical covariates, as well as tumor purity and keratinization-related programs. Functionally, TRIM29 suppressed tumor cell proliferation, migration, and epithelial-mesenchymal transition in vitro, and inhibited tumor growth and metastasis in a syngeneic mouse model. Mechanistically, TRIM29 activated tumor-suppressive pathways (e.g., p53) and epithelial markers (e.g., KRT5), while repressing oncogenic pathways (e.g., KRAS, IL6-JAK-STAT3). Unadjusted bulk transcriptome analyses suggested that TRIM29-high tumors exhibit an immune-cold phenotype with reduced immune infiltration. However, these associations attenuated after adjustment for tumor purity and keratinization programs. Notably, the syngeneic model provided orthogonal evidence that TRIM29 overexpression can decrease intratumoral CD8 + T-cell infiltration. Protein-protein interaction analysis identified KRT5 and TRAT1 as key interactors, suggesting that TRIM29 may preserve squamous differentiation while simultaneously attenuating anti-tumor immunity. Our findings support a context-dependent dual role of TRIM29 in LUSC, where it combines tumor-intrinsic suppression of malignant progression with potential remodeling of the tumor microenvironment. This study provides new insights into the complex role of TRIM29 in LUSC and underscores its potential as a therapeutic target, warranting further validation in cell-type–resolved and clinically annotated cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.